Peripheral vascular disease (PVD) is associated with a high cardiovascular morbidity and mortality. Intermittent claudication is the most common symptomatic manifestation of PVD, but is also an important predictor of cardiovascular death, increasing it by three-fold, and increasing all-cause mortality by two to five-fold. Hypertension is a common and important risk factor for vascular disorders, including PVD. Of hypertensives at presentation, about 2-5% have intermittent claudication, with this prevalence increasing with age. Similarly, 35-55% of patients with PVD at presentation also have hypertension. Patients who suffer from hypertension with PVD have a greatly increased risk of myocardial infarction and stroke. Apart from the epidemiolog-
Introduction
Peripheral vascular disease (PVD) is the cause of a large number of hospitalisations each year. In the United States of America, 9.6% of 'cardiovascular events' are due to PVD, requiring 63 000 hospital admissions every year. 1 In addition, PVD is associated with a significant morbidity and mortality. In a study in Finland, for example, patients with intermittent claudication had a three-fold excess risk of death over 5 years from cardiovascular causes, when compared to men without claudication. 2 This high adverse outcome is also illustrated by an Israeli study, where 44% of all men with intermittent claudication died within 21 years, when compared with 29% without PVD. 3 Hypertension is a common and important risk factor for all vascular disorders, including PVD. 4, 5 In hypertensive patients at presentation, between 2-5% have intermittent claudication, with this prevalence increasing with age. 6 Similarly, 35-55% of patients with PVD at presentation also have hypertension. [7] [8] [9] [10] [11] Apart from these epidemiological associations, hypertension also contributes to the pathogenesis of atherosclerosis, which is the basic underlying pathological process underlying PVD. [12] [13] [14] Indeed, hypertension, in common with PVD, is also associated with abnormalities of haemostasis and the lipid profile.
Although it seems logical that the treatment of hypertension should lead to a reduction in the incidence of PVD, none of the large placebo-controlled antihypertensive treatment trials have adequately addressed this question as a primary outcome measure. There is therefore an obvious need for more information on such outcomes especially since the two conditions are both common and closely related.
Epidemiology of PVD
Intermittent claudication is the most common symptomatic manifestation of PVD. Nevertheless these patients represent the tip of the iceberg as many more patients have asymptomatic PVD (Table 1) . The methods of case ascertainment with differing criteria for diagnosis and the diverse populations of varying ages which have been studied may explain the wide variation in the prevalence of PVD in the world literature.
In the Edinburgh Artery Study, which studied a population of 1592 subjects aged 55 to 74 years, 4.6% had intermittent claudication but in addition, 6.6% had major asymptomatic PVD diagnosed clinically and 15% had minor asymptomatic disease. 4 In a Sardinian population of people aged over 20 years, 4.7% had PVD, measured using a standard questionnaire together with Doppler blood flow studies although only 18.5% of these were symptomatic at the time of examination. 7 Variable findings have been noted in other studies. In an American study of 613 men and women, the prevalence of large vessel disease was 11.7%, small vessel disease 16% and combined large and small vessel involvement was present in 5.2% of participants. 15 In a different study, the same authors reported that patients with severe PVD had significantly elevated systolic blood pressure, although they fail to define what the term 'severe' meant. 16 In the Rotterdam Study of 7715 men and women aged over 55 years, PVD was present in 16.9% of men and 20.5% of women but symptomatic disease was only reported in 2.2% and 1.2% respectively; 17 similarly in Limburg, PVD was present in 8.6% of 3650 subjects but was symptomatic in only 3.8%. 18 In a Scandinavian sample of 10 962 aged 30-59 years, intermittent claudication was present in 2.1% of men and 1.8% of women 2 and in 10 059 Israeli men aged 40-65 years, 2.7% responded positively when asked about intermittent claudication symptoms. 19 One retrospective study of women from Belgium showed that of 45 proven cases of PVD, 16 (36%) had asymptomatic disease, whilst 19 (42%) had intermittent claudication and 10 (22%) had rest pain and necrosis. 12 Whilst there are much data on the prevalence of PVD, few studies have specifically addressed the incidence of PVD in large populations at follow up. The data from the TransAtlantic Inter-society Consensus (TASC) reveals that although hypertension is a risk factor for development of PVD and is predictor of mortality in these patients it is not the most significant. Furthermore it does not seem to predict disease progression in patients with established PVD. 20 In the Quebec Cardiovascular Study, 4570 men between the ages of 35 and 64 were followed up for 12 years. During this period, 188 developed intermittent claudication for the first time, this being an annual incidence of 41/10 000 per year. Those developing intermittent claudication were significantly more likely to have elevated blood pressure than the non-PVD examinees. 21 The 38-year data from The Framingham Study reported an increase in incidence of intermittent claudication from 0.9% over 4 years in men aged 45-54 to 2.5% in men aged 65-75 until the 75 to 84-year-old cohort, where the incidence decreased to 1.9% over 4 years. Importantly, this change was very strongly correlated with the presence of Stage 2 (or higher) hypertension (systolic blood pressure Ͼ160 mm Hg or diastolic blood pressure over 100).
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Hypertension as a contributor to PVD
Hypertension, and particularly the height of the systolic blood pressure, is a well established risk factor for heart disease and stroke. 4, 5 As far back as 1962 actuarial studies demonstrated that, as is now accepted, these complications are more closely associated with the systolic rather than the diastolic blood pressure elevation. 23 In the Glasgow Blood Pressure Clinic, it was even shown that there was no relationship between change in diastolic blood pressure and cardiovascular death. 24 Whilst the mortality from all causes is reduced by a reduction in systolic blood pressure, it remains 2-5 times higher than the mortality in the surrounding general population, 25 although there has been a recent trend for the cardiovascular mortality in hypertensive patients to return to that of the population at large. 26, 27 Follow-up data from the Framingham Study found a 2.5 to four-fold increased risk of PVD in men and women with hypertension. 5, 28 In a post mortem study of 1164 young men aged 15-34 years, 13.7% had renal changes indicative of hypertension and they had a higher prevalence of raised atherosclerotic lesions occupying Ͼ5% of the intimal area of the abdominal aorta of between 1.3 and 1.6-fold, compared to the normotensive group. 29 In these patients, the prevalence of abdominal aortic raised lesions was greater than that of raised lesions in the right coronary artery, which was somewhat unexpected, as hypertension is usually perceived as a greater risk factor for coronary artery disease. 5, 28 Nevertheless not all studies demonstrate a clear relation between hypertension and PVD. For example, the Reykjavik Study found a 55% decrease in the incidence of PVD in Icelandic men aged 60-70 years old, which was greater than the decrease in the incidence of coronary heart disease, although the presence of systolic or diastolic hypertension were shown to be not significantly different. 30 In an analysis from the Glasgow Blood Pressure clinic, of 1357 hypertensive men, 75 (5.5%) had probable or definite intermittent claudication and the prevalence was very clearly related to increasing age. However, intermittent claudication showed no relationship with the severity of the hypertension. 6 Is hypertension therefore a significant risk factor at presentation for PVD? In a large study from Italy, 35% of 1011 patients with PVD had hypertension at presentation and importantly, having both hypertension and PVD produced an odds ratio of 1.48 (P = 0.0056) for subsequent cardiovascular events. 11 This study showed that deaths from all causes were more frequent in patients with an ankle/brachial pressure ratio below 0.8. This observation was also confirmed in the SHEP (Systolic Hypertension in the Elderly Programme) study where a low ankle arm index (less than 0.9) in an older population as well as hypertension predicted a two to three-fold increased risk of cardiovascular mortality. 31 Of 510 Chinese patients with PVD in Hong Kong, 55% had hypertension which was exceeded only by the prevalence of smoking and elevated LDL cholesterol. 8 In a small study from Belgium of 45 female patients with proven PVD, arterial hypertension also proved to be a predictive risk factor. 12 An Italian case control study also showed a significantly greater prevalence of arterial hypertension (51.9 vs 9.8%) in PVD patients, 10 which was confirmed by Binaghi et al 7 where 21.6% of 27 patients with PVD had arterial hypertension. Finally, treated or untreated hypertension was found to be present in 40% of a population 84 patients with PVD aged under 65 years old with angiographically or laboratory-proven disease 9 ( Table 2 ).
Hypertension and aneurysm of the abdominal aorta
There has been some debate as to the prevalence of abdominal aortic aneurysm (AAA) in hypertensive patients. 32 This data also shows a much lower prevalence of AAA (defined as an abdominal aorta greater than 4.0 cm in diameter) in this age group (1.4%) than the other studies. It has great power having been conducted in 73 451 subjects, by far the largest. Although not all aneurysms are atherosclerotic they are clearly so in the vast majority and thus this aetiology has to be considered. As with most peripheral atherosclerotic disease, there is a male predominance at any age. The presence of diabetes mellitus appears paradoxically to have a protective effect with very few patients developing aneurysms.
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Renal artery stenosis
An important consideration is the association of PVD with both known and previously undiagnosed atherosclerotic renal artery stenosis (ARAS). It has been shown that 40% of patients undergoing abdominal arteriography for PVD have ARAS which was also present in 30% of patients undergoing coronary angiography, 34, 35 in contrast, the prevalence in those with PVD and hypertension was 34%. 36 It is apparent, however, that ARAS (unlike fibromuscular dysplasia) is unlikely to be the cause of hypertension per se but poor renal perfusion leading to activation of the renin-angiotensin-system more probably exaggerates the hypertension. While the effect of renal artery repair or angioplasty on the control of blood pressure has been disappointing, there is evidence that these procedures may help to preserve renal function. 37, 38 Several studies have also reported that renal artery revascularisation, with or without stenting has no advantages over oral antihypertensive therapy in the management of high blood pressure. 39 An important consideration is the effect of the treatment of hypertension in patients with ARAS. In particular, angiotensin converting enzyme inhibitors (ACE-I) should be used with caution in patients with known PVD because of the possibility of concurrent renal artery stenosis leading to over-rapid falls in blood and a deterioration in renal function. 40 Whilst this problem is probably overstated, and usually reversible, great caution is needed, therefore, when prescribing ACE-I in patients with peripheral, coronary, and for that matter, carotid artery disease, particularly if they are smokers. Renal function should also be assessed before and after a few days of starting ACE-I, even if excessive falls in blood pressure are not encountered.
Diabetes mellitus
As would be expected, the prevalence of PVD in patients suffering from diabetes mellitus (DM) increases in the presence of systolic hypertension in all racial groups. [41] [42] [43] [44] It has also been shown that, at the time of diagnosis, patients with non-insulin dependent diabetes mellitus (NIDDM) were shown to have no greater prevalence of macrovascular PVD than non-diabetics and that the vascular complication rate is associated with an increasing duration of the disease. 45 Furthermore there is evidence that if hypertension in diabetics is controlled, then the progression of PVD can be slowed. 46 
Pathophysiological considerations
Atherosclerotic lesions seem to occur at specific sites in patients with predetermined risk factors even if the exact mechanisms of their development is not completely clear. One contributing factor to the initiation of the plaque would appear to be haemodynamic forces and especially shear stresses.
Most atherosclerotic disease in the peripheral circulation tends to occur in places where there would be an expected change in the haemodynamic state; the abnormal flow state is accompanied by a known decrease in arterial compliance and increased blood velocity.
14,47 These 'pro-atherogenic' places are, broadly speaking, at bifurcations in arteries notably carotid, aortic and femoral, and the risk of developing these lesions is greatly increased in hypertensive patients.
The overall atherogenic process, however, is predominantly initiated and maintained by plaque lipids. In view of this, it is not surprising that dyslipidaemic states, such as that which occurs in association with hypertension as well as diabetes mellitus, causes an increased incidence of atherosclerotic disease. It has been shown in vitro that when low-density lipoproteins (LDL) are in contact with endothelial cells, they become oxidised to the active peroxide form. The oxidised LDL is avidly taken up by monocytes 48, 49 which attach to the endothelial cells on the adhesion molecules E-selectin and intracellular adhesion molecule-1 (ICAM-1) and migrate between them. Phagocytosis then occurs and the monocytes are transformed into the characteristic foam cells, the precursor of atherosclerosis. 50 An accumulation of these foam cells generates the so-called 'fatty streak' in the intima.
Although platelets play no part in the initiation of the plaque 51 when the fatty streak becomes of sufficient size for the covering endothelial layer to be disrupted platelets stick to the underlying matrix. The activated platelets release a number of factors, including platelet-derived growth factor (PDGF). 52 This causes proliferation of smooth muscle cells and their migration towards the intima, which causes further growth of the plaque and formation of the fibrous cap. The mature plaque thus has a covering of collagen secreted by migrated smooth muscle cells, covered with endothelium and a lipid interior. Rupture of the cap exposing the collagen matrix to the blood causes thrombus formation that may obstruct the vessel or become, once more, covered with a fibrous coat leading to further propagation of the lesion.
Patients with hypertension demonstrate abnormalities of vessel wall (endothelial dysfunction or damage), blood constituents (abnormal levels of haemostatic factors, platelet activation and fibrinolysis) and blood flow (rheology and flow reserve) suggesting that hypertension does confer a prothrombotic or hypercoagulable state. 53 These components appear to be related to target organ damage, longterm prognosis and are altered by treatment. 53, 54 Many studies have also demonstrated abnormalities in coagulation factors, platelets and the endothelium in patients with PVD, where they are predictive of adverse outcome. For example, elevated fibrin Ddimer levels, an index of thrombogenesis and fibrin turnover, 55 have been found in patients with PVD, which correlate with clinical, haemodynamic and angiographic severity. 56 In one cross-sectional study of patients with carotid atherosclerosis, patients with increased intima-media thickness of carotid arteries on B-mode ultrasound scanning also had higher fibrin D-dimer levels compared to controls. 57 The increased fibrin turnover in cigarette-smoking (the major risk factor for PVD) is likely to be one mechanism by which smoking contributes to PVD.
The measurement of fibrin D-dimer has been shown to have prognostic implications in patients with PVD. In a study of 617 patients with claudication, baseline fibrin D-dimer levels were closely related to future coronary events (both fatal and nonfatal, with a relative risk of 4.4 between upper and lower quintiles) and also with haemodynamic progression of peripheral arterial disease. 58 This risk is similar to that seen in healthy men. 59 Perhaps infection may be a common contributor to both hypertension and PVD. Indeed, associations have been reported between Chlamydia pneumoniae infection and both hypertension and atherosclerosis. 60, 61 Indeed C. pneumoniae is a pathogen which is well recognised to be associated with atherosclerotic plaques and cardiovascular disease. 60 In the study by Cook et al, 61 35% of hypertensive patients and 17.9% of matched control subjects had antibody titre levels consistent with C. pneumoniae infection, with an odds ratio of 2.5 (95% confidence interval, 1.3 to 4.7). Nevertheless there were no significant differences in antibody levels between patients with left ventricular hypertrophy and hypercoagulability or endothelial dysfunction in this study.
Therapeutic considerations
Treatment of hypertension in patients symptomatic of PVD needs careful consideration (Table 4) . Current guidelines recommend an individualised approach towards using antihypertensive agents, although it is recognised that the greatest trial experience is with the beta-blockers and diuretics. 62 For example, beta-blockers are recommended as 'first-line' treatment for hypertension, especially in the presence of associated coronary disease. Nevertheless atenolol has shown to reduce the walking distance in claudicants in one study 63 but this does not seem to be a class effect, as the same study found an increase in walking distance with celiprolol. One randomised placebo-controlled trial found no significant change in claudication distance in patients with angina randomised to beta-blockers. 64 A meta-
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analysis of the trials of beta-blockers in patients with intermittent claudication demonstrated that in patients with mild or moderate claudication betablockers have no detrimental effect on the walking distance. 65 Nevertheless, patients with rest pain or gangrene should certainly not be given beta-blockers. Overall, beta-blockers should be administered with some caution in patients with proven severe PVD. 66 The ACE inhibitors are widely used in the treatment of hypertension and heart failure. In patients with PVD and hypertension they have been shown to increase the peripheral perfusion and walking distance and therefore appear useful in this setting. [67] [68] [69] Furthermore, the HOPE trial demonstrated that ACE inhibitors given to high risk cardiovascular patients without heart failure was beneficial in preventing cardiovascular end points. 70 This group demonstrated a relative risk of about 0.75 for patients with PVD treated with captopril compared to those on placebo. However, caution is advised if associated renal artery stenosis is present, as such patients may develop significant hypotension and an acute deterioration in renal function.
The alpha receptor antagonists, such as prazosin or doxazosin, are used widely in combination treatment for high blood pressure, although as a class of drugs they do not appear to have a significant effect on symptoms of peripheral artery disease. 71, 72 Similar comments can be made for the thiazide diuretics, which generally have little effect on PVD, and are safe.
The calcium channel antagonists are effective in the reduction of blood pressure in hypertensives. Some trials have shown significant benefit using these agents on PVD symptoms [73] [74] [75] although others have demonstrated no improvement. 64, 76 Calcium channel antagonists therefore are certainly not contraindicated in PVD and their use might even be beneficial.
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Interventions
Hypertension has repeatedly been shown as a risk factor for coronary artery disease and stroke but also by treatment of hypertension, the incidence of these complications and all their sequelae, are significantly reduced. However, intervention trials in hypertension often do not include PVD or its symptomatic manifestations, such as intermittent claudication, in the outcomes. One exception may be a small follow-up trial after the SHEP study, which showed a decrease in mortality from cardiovascular causes for treated patients with known PVD. 78 Perhaps it is time that more trials addressed this issue, especially since the two conditions (that is, hypertension and PVD) are commonly encountered together but the association is often forgotten.
Therapeutic interventions may affect smaller vessels. For example, hypertension may affect smallartery structure, with correlations between Journal of Human Hypertension media:lumen ratio and diastolic blood pressure, with the media of small arteries taken from the gluteal region being significantly increased and the lumen diameter smaller in untreated hypertensives. 79 This group also showed that treatment of hypertension with both angiotensin receptor antagonist, losartan, and the ACE inhibitor, cilazapril, significantly improved arterial structure and endothelial function, when compared with atenolol. 80, 81 This again suggests that although the jury may still be out on the beta-blockers in PVD there is almost certainly not the potential benefit seen with other classes of drug.
Conclusion
There is evidently a clear association between PVD and hypertension although its relative risk may not be as high as for smoking or diabetes mellitus. Large epidemiological studies have shown that not only is hypertension a risk factor for PVD but also the risk seems to increase with increasing systolic blood pressure and age (up to about 75 years old). Furthermore, about 40% of patients attending vascular clinics with PVD have hypertension.
Nevertheless why the association between hypertension and PVD is not as strong as that observed between hypertension and coronary heart disease is not clear, although one explanation is that PVD presents later due to the capacity for collateralisation in lower limb vessels being greater than that of the coronary circulation. Recent advances in the understanding of the initiation of atherosclerosis suggest that flow characteristics might perhaps play some part. The lack of published data on change in incidence of PVD in the large placebo-controlled hypertension trials means that the conclusion that treatment of blood pressure may reduce PVD incidence is unproven but possibly logical.
